Regenxbio – Talk Bio

Regenxbio Reports Consistent One-Year Benefit for DMD Gene Therapy RGX-202

2 days ago talkbio0Tagged AFFINITY DUCHENNE trial, Biological Markers, Clinical Trials, Functional, gene therapy, Muscular Dystrophy, Duchenne, Phase III, Regenxbio, SLC6A8 Inhibitor RGX-202

Regenxbio; DMD; Duchenne muscular dystrophy; RGX-202; gene therapy; AFFINITY DUCHENNE trial; clinical trial; microdystrophin; biomarker; phase I/II; functional data

RegenXBio Secures Up to $250 Million by Monetizing Royalties from Zolgensma and Two Gene Therapies

3 weeks ago talkbio0Tagged gene therapy, HealthCare Royalty, milestone payments, non-dilutive financing, Regenxbio, RGX-111, RGX-121, royalty monetization, Zolgensma

RegenXBio; Zolgensma; gene therapy; royalty monetization; HealthCare Royalty; RGX-121; RGX-111; non-dilutive financing; biotech; milestone payments

RegenXBio Secures $110M Upfront in Strategic Partnership with Nippon Shinyaku for Hunter Syndrome Gene Therapy

5 months ago talkbio0Tagged Gene, gene therapy, Mucopolysaccharidosis II, Nippon, Regenxbio, RGX-111, RGX-121, Shinyaku, strategic partnership

RegenXBio, Hunter syndrome, Gene therapy, Nippon Shinyaku, Strategic partnership, Rare metabolic disorder, Mucopolysaccharidosis type II (MPS II), RGX-121, RGX-111

Regenxbio Advances Duchenne Muscular Dystrophy Gene Therapy to Pivotal Studies, Potentially Challenging Sarepta’s Dominance

7 months ago talkbio0Tagged Approved, Biologics License Application, DMD, Duchenne, ELEVIDYS, gene therapy, Muscular Dystrophy, Muscular Dystrophy, Duchenne, Regenxbio, SLC6A8 Inhibitor RGX-202, United States Food and Drug Administration

Regenxbio, Sarepta Therapeutics, Duchenne Muscular Dystrophy (DMD), Gene Therapy, RGX-202, Elevidys, Pivotal Studies, Biologics License Application (BLA), FDA Approval